NCT03736759

Brief Summary

This study evaluates whether resistance exercise will improve immune responses to the seasonal influenza vaccine in older adults. One third of the participants will perform exercise in the arm that receives the vaccine, one third of the participants will perform the same exercise in the arm that does not receive the vaccine, and one third will only receive the vaccine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 8, 2018

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 7, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 9, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2019

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

May 17, 2022

Status Verified

May 1, 2022

Enrollment Period

7 months

First QC Date

November 7, 2018

Last Update Submit

May 16, 2022

Conditions

Keywords

exercisevaccineolder adults

Outcome Measures

Primary Outcomes (4)

  • Cell mediated immunity change at 6 weeks post-vaccine

    The change in the peripheral blood mononuclear cell response to overnight ex vivo culture with the seasonal quadrivalent vaccine detected via Interferon-gamma ELISPOT will be calculated from baseline at 6 weeks post-vaccine

    baseline and 6 weeks

  • Antibody titer change at 6 weeks post-vaccine

    The change in influenza-specific antibody titers in serum measured by hemagglutination inhibition assay will be calculated from baseline at 6 weeks post-vaccine

    baseline and 6 weeks

  • Cell mediated immunity change at 6 months post-vaccine

    The change in the peripheral blood mononuclear cell response to overnight ex vivo culture with the seasonal quadrivalent vaccine detected via Interferon-gamma ELISPOT will be calculated from baseline at 6 months post-vaccine

    baseline and 6 months

  • Antibody titer change at 6 months post-vaccine

    The change in influenza-specific antibody titers in serum measured by hemagglutination inhibition assay will be calculated from baseline at 6 months post-vaccine

    baseline and 6 months

Secondary Outcomes (2)

  • Muscle soreness

    7 days

  • Influenza-like symptoms

    Measured monthly for six months

Study Arms (3)

Exercise and vaccine in same arm

EXPERIMENTAL

20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm

Behavioral: Exercise

Exercise and vaccine in different arms

ACTIVE COMPARATOR

20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm

Behavioral: Exercise

vaccine only

NO INTERVENTION

20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm

Interventions

ExerciseBEHAVIORAL

10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating

Exercise and vaccine in different armsExercise and vaccine in same arm

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • non-frail older adult (≥65 years old) of any sex and race/ethnicity
  • non-smokers (\>10 yrs)
  • meets American College of Sports Medicine criteria for participation in exercise
  • US resident

You may not qualify if:

  • underlying medical problems that contraindicate supervised resistance exercise
  • past or present history of autoimmune disease, HIV, hepatitis, stroke, or cardiovascular disease
  • current debilitating arthritis of the shoulder
  • central or peripheral nervous disorders
  • bedridden in the past three months
  • history of vaccine-related allergies, or severe egg allergy;
  • physician-confirmed influenza infection in the prior year
  • regular user of corticosteroids
  • functional or cognitive impairment that would limit exercise performance or prohibit informed consent
  • blood pressure greater than 160/90
  • participation in resistance arm exercises in the prior 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Houston

Houston, Texas, 77204, United States

Location

Related Publications (1)

  • Elzayat MT, Markofski MM, Simpson RJ, Laughlin M, LaVoy EC. No Effect of Acute Eccentric Resistance Exercise on Immune Responses to Influenza Vaccination in Older Adults: A Randomized Control Trial. Front Physiol. 2021 Aug 12;12:713183. doi: 10.3389/fphys.2021.713183. eCollection 2021.

MeSH Terms

Conditions

Influenza, HumanMotor Activity

Interventions

Exercise

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsOrthomyxoviridae InfectionsRNA Virus InfectionsVirus DiseasesRespiratory Tract DiseasesBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Emily C LaVoy, PhD

    University of Houston

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 7, 2018

First Posted

November 9, 2018

Study Start

October 8, 2018

Primary Completion

April 30, 2019

Study Completion

April 1, 2021

Last Updated

May 17, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will share

De-identified individual participant data for all primary and secondary outcome measures will be made available.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Data will be available within 6 months of study completion.
Access Criteria
Data access requests will be reviewed by an external independent review panel. Requestors will be required to sign a Data Access Agreement.

Locations